Can central adiposity and insulin resistance suppress testosterone, and can low testosterone worsen visceral fat and insulin resistance?

The relationship between metabolic dysfunction and testosterone deficiency is a bidirectional, self-reinforcing pathological loop. In this cycle, metabolic impairment suppresses the hypothalamic-pituitary-gonadal (HPG) axis, and the resulting low testosterone further degrades metabolic health.

Mechanisms of metabolic gonadal suppression

• Visceral fat-driven suppression: Visceral adiposity increases aromatase activity, accelerating the conversion of testosterone to estradiol. This excess estradiol exerts potent negative feedback on hypothalamic GnRH and pituitary LH/FSH secretion. Concurrently, elevated pro-inflammatory cytokines and leptin disrupt kisspeptin-dependent signaling, reducing LH pulse amplitude.
• Insulin-mediated pathways: Insulin resistance and chronic hyperinsulinemia act directly on the liver to suppress the synthesis of Sex Hormone-Binding Globulin (SHBG). Furthermore, hyperinsulinemia impairs kisspeptin-mediated GnRH release and blunts LH-stimulated steroidogenesis in testicular Leydig cells.
• Hyperglycemic effects: In type 2 diabetes, chronic hyperglycemia impairs the hypothalamic GnRH pulse generator, directly reducing LH pulse frequency and contributing to functional hypogonadotropic hypogonadism.

Low testosterone's impact on fat gain and insulin resistance

• Adipose tissue hypertrophy: Testosterone normally stimulates lipolysis by upregulating beta-adrenergic receptor expression and activating hormone-sensitive lipase. Deficiency in testosterone reduces this androgen receptor-mediated pathway while disinhibiting lipoprotein lipase (LPL) activity, accelerating triglyceride accumulation and visceral adipocyte storage.
• Impaired insulin signaling: Hypogonadism decreases insulin-sensitive muscle mass and alters adipokine profiles. At the cellular level, low testosterone downregulates critical insulin signaling genes—including IRS-1, AKT-2, and GLUT4—which elevates HOMA-IR. Clinical administration of testosterone replacement therapy consistently reverses these molecular defects, improving systemic glucose infusion rates and reducing waist circumference.

Bottom line

• Metabolic dysfunction and low testosterone form a pathological, bidirectional loop where visceral adiposity, hyperinsulinemia, and hyperglycemia suppress HPG-axis dynamics, while the resulting androgen deficiency impairs cellular insulin signaling and drives visceral lipid accumulation.